The combination of sotigalimab (APX005M) and nivolumab (Opdivo) elicited durable responses with a reasonable safety profile in patients with melanoma who were refractory to anti–PD-1 therapy, according to data from a phase 2 trial (NCT03123783).
Archive | Health Professionals
Sotigalimab Plus Nivolumab Shows Encouraging Activity in Anti–PD-1 Refractory Melanoma
Posted in Melanoma News, Health Professionals, Clinical Trials
What’s Ahead for Melanoma Management
Immunotherapy, intralesional treatments, multidisciplinary care teams define rapidly-evolving multimodal approach.
Posted in Melanoma News, Health Professionals, Of Interest
Apatinib Prompts Responses in Patients With Recurrent Melanoma
The drug yielded partial responses in 2 of 15 patients in this single-arm, phase 2 study.
Posted in Melanoma News, Health Professionals, Of Interest
Multiple Myeloma May Increase Incidence of Melanoma
Patients with multiple myeloma (MM) may be more likely to develop melanoma than the general population, according to a poster presented at 2022 American College of Mohs Surgery Annual Meeting. They also may face a higher overall but not melanomas-specific mortality rate, the findings showed.
Posted in Melanoma News, Health Professionals, Of Interest
 |
 |
 |
 |
